Research design considerations for chronic pain prevention clinical trials
Jennifer S. Gewandter(Heinrich Heine University Düsseldorf), Gary A. Walco(Seattle Children's Hospital), Joel Katz(York University), Richard Malamut(Teva Pharmaceuticals (Czechia)), Christine Rauschkolb(Johnson & Johnson (United States)), Clifford J. Woolf(Boston University), Bob A. Rappaport, Henrik Kehlet(University of Copenhagen), Ernest A. Kopecky(Endo Pharmaceuticals (United States)), Ole Graff(GlaxoSmithKline (Netherlands)), Rachel A. Kitt(University of Rochester), John D. Markman(University of Rochester), Michael A. Ashburn(University of Pennsylvania), James P. Robinson(University of Minnesota), Steven Z. George(University of Florida), Michael McDermott(University of Leeds), Robert H. Dworkin(University of Rochester), Ilona Steigerwald(Grünenthal Group (Germany)), Jeffrey Tobias(Jazz Pharmaceuticals (United States)), Anne Louise Oaklander(Harvard University Press), Laurie B. Burke(Center for Drug Evaluation and Research), Roger B. Fillingim(University of Florida), Michael Polydefkis(Université Paris-Sud), John T. Farrar(University of Pennsylvania), Srinivasa N. Raja(Johns Hopkins Medicine), Pamela Pierce Palmer(AcelRx Pharmaceuticals (United States)), Dan Ziegler(Heinrich Heine University Düsseldorf), Smriti Iyengar(Eli Lilly (United States)), Dennis C. Turk(University of Washington), Penney Cowan(American Chronic Pain Association), Ian Gilron(Apple (Israel)), Veeraindar Goli(Duke University), Gary W. Jay(North Carolina Virtual Public School)
Cited by 143
Related Papers
The biopsychosocial approach to chronic pain: Scientific advances and future directions.
|Psychological Bulletin|2007|3.3k
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Neuropathic pain
|Nature Reviews Disease Primers|2017|2k